patent period

Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia.

patent period

The time during a parasitic disease that organisms are demonstrable in the body.
See also: period


1. open, unobstructed, or not closed.
2. apparent, evident.

patent ductus arteriosus (PDA)
abnormal persistence of an open lumen in the ductus arteriosus, between the aorta and the pulmonary artery, after birth. The ductus arteriosus is open during prenatal life, allowing most of the blood of the fetus to bypass the lungs, but normally this channel closes shortly before birth. When the ductus arteriosus remains open, it places special burdens on the left ventricle and causes a diminished blood flow in the aorta. May remain open for up to 5 days in foals. One of the most common congenital heart defects in dogs, but less common in cats. Causes a continuous 'machinery' murmur loud in systole, soft in diastole, and 'bounding' pulse.
patent ductus venosus
see ductus venosus.
patent foramen ovale
see foramen ovale (1).
patent medicine
a drug or remedy protected by a trademark, available without a prescription.
patent period
the period during a disease in which the causative agent can be detected by clinicopathological tests, e.g. for helminth eggs.
patent urachus
the urachus persists after birth and allows urine to drip out of the bladder through the umbilicus. See also urachus.
patent ventricular septum
includes several entities characterized by incomplete closure of ventricular wall. Characterized by palpable cardiac thrill and audible pansystolic murmur on both sides of the chest at birth, accompanied by exercise intolerance and developing dyspnea at rest.
References in periodicals archive ?
Drugs developed and patented by any pharmaceutical company can be produced generically by other competent companies once the patent period ends.
Because patent applicants must fully disclose their invention in the application, patents are generally considered to encourage more research and investment in new methods and processes aimed at further developing the invention after its patent period expires.
The patent prevents other companies from making and selling the product during the patent period.
It reached a reasonable settlement with Upshur-Smith, paying $60 million for the products in development for which it obtained rights, and agreeing to settle the patent litigation with Upshur by splitting the remaining patent period (giving Schering an additional five years of exclusivity, and enabling Upshur to enter the market five years before expiration of the patent).